Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
M6495 (Anti-ADAMTS-5 Nanobody) in Symptomatic Knee Osteoarthritis
NCT03583346Phase 1Completed
- Sponsor
- Merck KGaA
- Start
- Aug 2018
- Primary completion
- Jul 2019
- Modality
- Nanobodies (VHH), Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in osteoarthritis (OA) comparing M6495 with Placebo (2 arms). Primary endpoints: Treatment-emergent Adverse Events, Clinically Significant Change in Vital Signs, Laboratory Parameters and ECG Findings and 1 more. Started Aug 2018; status: completed.
02
Drugs
isecarosmab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT03583346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583346.